Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty 25/10/2017 by Intellectual Property Watch 11 Comments Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment. The Initiative for Medicines, Access & Knowledge (I-MAK) filed the first-ever set of US patent challenges against sofosbuvir with the US Patent Trial and Appeal Board. The group challenged six patents, arguing that sofosbuvir’s patents do not meet patentability criteria such as novelty and non-obviousness, according to a press release. The group also issued a new white paper “America’s Overspend: How the Pharmaceutical Patent Problem is Fueling High Drug Prices.” The white paper finds that unmerited patents and other strategies allegedly used by the pharmaceutical industry to delay competition on three major cancer and hepatitis C treatments will cause more than $55 billion in excess costs to payers and taxpayers. The paper examines three of America’s most expensive and widely prescribed drugs for cancer and hepatitis C: Revlimid, Sovaldi and Gleevec. According to the press release, the market for medicines is not working, and removing unmerited patents will allow more affordable generic drugs to be introduced much sooner. The release states that pharmaceutical drugs patents fail too often to meet the standards of US law. “Pharmaceutical corporations are over-patenting drugs even when there is no new science that justifies their exclusivity and are stacking up as many unmerited patents as possible to prolong their monopolies and block cheaper generics from entering the market,” it says. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
[…] Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty Intellectual Property Watch […] Reply
[…] In November, I-MAK filed the first-ever set of US patent challenges against sofosbuvir with the US Patent Trial and Appeal Board. I-MAK challenged six patents, arguing that the sofosbuvir’s patents do not meet patentability criteria such as novelty and non-obviousness (IPW, IP & Health, 25 October 2017). […] Reply
[…] In November, I-MAK filed the first-ever set of US patent challenges against sofosbuvir with the US Patent Trial and Appeal Board. I-MAK challenged six patents, arguing that the sofosbuvir’s patents do not meet patentability criteria such as novelty and non-obviousness (IPW, IP & Health, 25 October 2017). […] Reply
[…] В ноябре I-MAK оспорила ряд патентов на софосбувир в США в Комиссии по рассмотрениям патентных споров. I-MAK оспорила шесть патентов, аргументируя это тем, что патенты на софосбувир не соответствуют критериям новизны и неочевидности (IPW, IP & Health, 25 октября 2017 г.). […] Reply
[…] do sofosbuvir não atendem a critérios de patenteabilidade como novidade e não obviedade (IPW, IP & Health, 25 October […] Reply
[…] В ноябре I-MAK оспорила ряд патентов на софосбувир в США в Комиссии по рассмотрениям патентных споров. I-MAK оспорила шесть патентов, аргументируя это тем, что патенты на софосбувир не соответствуют критериям новизны и неочевидности (IPW, IP & Health, 25 октября 2017 г.). […] Reply
[…] affirmant qu’ils ne remplissaient pas les critères de nouveauté et d’activité non évidente (IPW, IP & Health, 25 octobre 2017, en […] Reply
[…] En noviembre, I-MAK presentó el primer conjunto de impugnaciones de patentes estadounidenses respecto del sofosbuvir ante la Junta de Juicios y Apelaciones sobre Patentes de Estados Unidos. I-MAK impugnó seis patentes, alegando que las patentes del sofosbuvir no cumplen los requisitos de patentabilidad, como la novedad y la no evidencia (IPW, propiedad intelectual y salud, 25 de octubre de 2017). […] Reply
[…] В ноябре I-MAK оспорила ряд патентов на софосбувир в США в Комиссии по рассмотрениям патентных споров. I-MAK оспорила шесть патентов, аргументируя это тем, что патенты на софосбувир не соответствуют критериям новизны и неочевидности (IPW, IP & Health, 25 октября 2017 г.). […] Reply
